August 19, 2009 | Xconomy

Why would a Big Pharma company want to remake itself as a biotech? The era of biologics—genetically engineered protein drugs made in living cells—is upon us. Biologics now account for 20 percent of the global drug market. By 2008, five of the top 10 drugs in sales were biologics, and by 2014 biologics are expected to occupy six of the top ten positions. You do the math.

August 20, 2009 | Minneapolis Star Tribune

Few people believe in the promise of biotechnology more passionately than Steven Burrill. Investors and executives flock to his conferences and eagerly digest his annual "State of the Biotech Industry" report. But some are scratching their heads over the San Francisco vc's decision to invest up to $1 billion to convert an elk farm in southern Minnesota into a bioscience incubator.

August 19, 2009 | peHUB

Over a dozen IBM execs have descended on Sao Paolo this week, to spearhead the expansion of Big Blue’s venture capital group in Brazil.

August 18, 2009 | Inside Higher Ed

A large part of the much-ballyhooed decline in the international standing of American higher education can be attributed to the fact that other countries have finally gotten more serious about pursuing excellence in and expanding access to their postsecondary systems -- which is not exactly a sign of U.S. failure.

August 17, 2009 | Castle Guard Partners

Although the U.S. is far from out of the woods, we have avoided sinking into a depression, prevented a systemic meltdown of the financial system, and taken positive steps to thaw the credit markets and increase lending activity. However, the government’s efforts to revive the credit markets have largely excluded a significant driver of the U.S. economy – middle market companies.